A trial to investigate alferminogene tadenovec in patients with stable angina
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 May 2015
At a glance
- Drugs Alferminogene-tadenovec (Primary)
- Indications Angina pectoris; Myocardial ischaemia
- Focus Therapeutic Use
- Acronyms AGENT-2
- 11 May 2015 Results published in an Angionetics media release.
- 05 Nov 2010 New trial record.